Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Protein Networks02:26

Protein Networks

4.5K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Survival Analysis01:21

Cancer Survival Analysis

645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Vaccines01:30

Cancer Vaccines

952
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
952
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of a miRNAs signature as potential biomarker of mesenchymal phenotype in neuroblastoma patients.

Biomarker research·2025
Same author

Semi-supervised graph learning for underwater source localization using ship-of-opportunity spectrograms.

The Journal of the Acoustical Society of America·2025
Same author

Artificial Intelligence and Chromothripsis.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Adjunct psychomotor trauma exposure in the treatment of post-traumatic stress disorder: a case series.

European journal of psychotraumatology·2025
Same author

Unified modeling language for patient-centered telerehabilitation: A comprehensive framework integrating medical and biopsychosocial pathways.

International journal of medical informatics·2025
Same author

Plasma-derived extracellular vesicles miR-335-5p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma.

Journal of experimental & clinical cancer research : CR·2024

Related Experiment Video

Updated: Jan 15, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K

From Predicting Cancer Treatment Response to Identifying Novel Therapeutic Targets using Graph Neural Networks.

Leila Outemzabet, Nicolas Gaud, Aurelie Bertaux

    IEEE Journal of Biomedical and Health Informatics
    |October 16, 2025
    PubMed
    Summary

    This study introduces TIGENet, an interpretable AI model that predicts cancer therapy response and identifies key genes driving resistance. This aids in developing personalized treatments for improved patient survival in oncology.

    More Related Videos

    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
    03:08

    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

    Published on: October 3, 2025

    895
    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
    09:33

    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

    Published on: August 25, 2023

    1.6K

    Related Experiment Videos

    Last Updated: Jan 15, 2026

    Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
    04:09

    Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

    Published on: October 10, 2018

    8.6K
    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
    03:08

    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

    Published on: October 3, 2025

    895
    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
    09:33

    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

    Published on: August 25, 2023

    1.6K

    Area of Science:

    • Oncology and Computational Biology
    • Genomics and Bioinformatics

    Background:

    • Cancer treatment resistance significantly impacts patient survival, necessitating predictive models.
    • Understanding resistance mechanisms is vital for developing effective therapeutic strategies.

    Purpose of the Study:

    • To introduce TIGENet, an interpretable model for predicting cancer therapy response.
    • To identify potential therapeutic targets and key genes involved in treatment resistance.

    Main Methods:

    • Integration of a variational autoencoder for dimensionality reduction.
    • Application of a Graph Neural Network model for predicting patient responses.
    • Utilizing a graph explainer for identifying influential genes.

    Main Results:

    • TIGENet successfully predicts patient response to cancer treatments using transcriptomic and clinical data.
    • Identified key molecular factors and genes associated with treatment resistance in breast cancer.
    • Highlighted influential genes driving model predictions for enhanced interpretability.

    Conclusions:

    • TIGENet offers an interpretable approach to predicting cancer therapy response and resistance.
    • Findings support the advancement of personalized therapeutic interventions in oncology.
    • The model aids in identifying patients at risk of resistance and relevant molecular drivers.